Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Plus Therapeutics (PSTV) Current Deferred Revenue (2016 - 2025)

Plus Therapeutics (PSTV) has disclosed Current Deferred Revenue for 12 consecutive years, with $2.0 million as the latest value for Q3 2025.

  • On a quarterly basis, Current Deferred Revenue rose 134.76% to $2.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was $2.0 million, a 134.76% increase, with the full-year FY2024 number at $927000.0, changed N/A from a year prior.
  • Current Deferred Revenue was $2.0 million for Q3 2025 at Plus Therapeutics, up from $927000.0 in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $2.3 million in Q2 2024 to a low of $247000.0 in Q1 2024.
  • A 3-year average of $1.2 million and a median of $1.0 million in 2023 define the central range for Current Deferred Revenue.
  • Peak YoY movement for Current Deferred Revenue: tumbled 78.28% in 2024, then skyrocketed 425.1% in 2025.
  • Plus Therapeutics' Current Deferred Revenue stood at $1.1 million in 2023, then dropped by 18.47% to $927000.0 in 2024, then surged by 112.73% to $2.0 million in 2025.
  • Per Business Quant, the three most recent readings for PSTV's Current Deferred Revenue are $2.0 million (Q3 2025), $927000.0 (Q2 2025), and $1.3 million (Q1 2025).